{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:59:53Z","timestamp":1790398793377,"version":"4.1.0"},"reference-count":15,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DD&amp;T"],"published-print":{"date-parts":[[2026,8,31]]},"DOI":"10.5582\/ddt.2026.01051","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T22:10:19Z","timestamp":1786659019000},"page":"354-356","source":"Crossref","is-referenced-by-count":0,"title":["Enlicitide: The first oral PCSK9 inhibitor approved for treatment of hypercholesterolemia"],"prefix":"10.5582","volume":"20","author":[{"given":"Yueyi","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Stein JH, Tattersall MC. Familial Hypercholesterolemia. JAMA. 2026. doi: 10.1001\/jama.2026.8822.","DOI":"10.1001\/jama.2026.8822"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Ference BA, Ginsberg HN, Graham I, <i>et al<\/i>. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017; 38:2459-2472.","DOI":"10.1093\/eurheartj\/ehx144"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Collaboration NCDRF. Repositioning of the global epicentre of non-optimal cholesterol. Nature. 2020; 582:73-77.","DOI":"10.1038\/s41586-020-2338-1"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Palloni MC, Farella T, Faggiano A, Vatri M, Fattirolli F, Angelino E, Ambrosetti M, Ruscica M, Corsini A, Carugo S, Poli A, Faggiano P. LDL-cholesterol distance to target: A practical tool for guiding lipid-lowering treatment decisions. Atheroscler Plus. 2026; 65:100574.","DOI":"10.1016\/j.athplu.2026.100574"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Zachariah D, Kakooza D, Pothas S, Thomas A, Kruger L. Statin therapy and cardiovascular prevention: Contemporary evidence, challenges, and future directions-A narrative review. Int J Environ Res Public Health. 2026; 23:921.","DOI":"10.3390\/ijerph23070921"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Blumenthal RS, Morris PB, Gaudino M, <i>et al.<\/i> 2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2026; 87:2624-2757.","DOI":"10.1016\/j.jacc.2025.11.016"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017; 376:1713-1722.","DOI":"10.1056\/NEJMoa1615664"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Schwartz GG, Steg PG, Szarek M, <i>et al<\/i>. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018; 379:2097-2107.","DOI":"10.1056\/NEJMoa1801174"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, Bisch JA, Richardson T, Jaros M, Wijngaard PLJ, Kastelein JJP, ORION-10 and ORION-11 Investigators. Two Phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020; 382:1507-1519.","DOI":"10.1056\/NEJMoa1912387"},{"key":"10","unstructured":"10. US Food and Drug Administration. FDA approves first oral therapy that inhibits proprotein convertase subtilisin\/kexin type 9 (PCSK9) to lower bad cholesterol in adults with high cholesterol. <i>https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-oral-pcsk9-inhibitor-lower-ldl-cholesterol-adults-high-cholesterol<\/i> (accessed July 25, 2026)."},{"key":"11","unstructured":"11. MERCK. Merck&apos;s LIPFENDRA<sup>\u00ae<\/sup> (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia. <i>https:\/\/www.merck.com\/news\/mercks-lipfendra-enlicitide-is-the-first-and-only-once-daily-oral-pcsk9-inhibitor-approved-by-the-u-s-fda-to-reduce-ldl-c-in-adults-with-hypercholesterolemia\/<\/i> (accessed July 27, 2026)."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Johns DG, Campeau LC, Banka P, <i>et al.<\/i> Orally bioavailable macrocyclic peptide that inhibits binding of PCSK9 to the low density lipoprotein receptor. Circulation. 2023; 148:144-158.","DOI":"10.1161\/CIRCULATIONAHA.122.063372"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Navar AM, Mikhailova E, Catapano AL, <i>et al<\/i>. A placebo-controlled trial of the oral PCSK9 inhibitor enlicitide. N Engl J Med. 2026; 394:529-539.","DOI":"10.1056\/NEJMoa2511002"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Ballantyne CM, Gellis L, Tardif JC, Banka P, Navar AM, Asprusten EA, Scott R, Stroes ESG, Froman S, Mendizabal G, Wang F, Catapano AL. Efficacy and safety of oral PCSK9 inhibitor enlicitide in adults with heterozygous familial hypercholesterolemia: A randomized clinical trial. JAMA. 2026; 335:129-139.","DOI":"10.1001\/jama.2025.20620"},{"key":"15","unstructured":"15. ClinicalTrials.gov. Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK- 0616-015) CORALreef Outcomes. <i>https:\/\/clinicaltrials.gov\/study\/NCT06008756<\/i> (accessed July 28, 2026)."}],"container-title":["Drug Discoveries &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/20\/4\/20_2026.01051\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:30:01Z","timestamp":1790397001000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/20\/4\/20_2026.01051\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5582\/ddt.2026.01051","relation":{},"ISSN":["1881-7831","1881-784X"],"issn-type":[{"value":"1881-7831","type":"print"},{"value":"1881-784X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"article-number":"2026.01051"}}